Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Venous Thromboembolism
99%
Direct Oral Anticoagulants
79%
Anticoagulation
67%
Thrombocytopenia
61%
Aspirin
59%
Platelets
58%
Atrial Fibrillation
48%
Thrombosis
46%
Thrombin Generation
45%
Low Molecular Weight Heparin
45%
Bleeding
42%
Antiplatelet Therapy
41%
Procoagulant Potential
38%
Pregnancy Disorders
36%
COVID-19
35%
In Cancer
34%
Cancer Patients
34%
Clinical Outcomes
33%
Clopidogrel
33%
Type 2 Diabetes Mellitus (T2DM)
32%
Endogenous Thrombin Potential
32%
Bleeding Risk
31%
Patients with Hematological Malignancies
31%
Hazard Ratio
30%
Apixaban
28%
95% Confidence Interval
27%
Population-based Cohort Study
26%
Arterial Thromboembolism
26%
Platelet Count
25%
Hematological Malignancies
23%
Platelet Adhesion
22%
Cumulative Incidence
21%
Patients with Cancer
20%
Dose Adjustment
20%
Platelet Inhibition
20%
Platelet Activation
20%
Chemotherapy
20%
Immune Thrombocytopenic Purpura
19%
Antithrombotic Therapy
19%
Hemostasis
19%
Cancer-associated Thrombosis
18%
Flow Conditions
18%
Antiplatelet Agents
18%
Intracranial Hemorrhage
18%
Type 2 Diabetic Patients
18%
Retrospective Cohort Study
18%
Malignant Superior Vena Cava Syndrome
17%
Fragility Hip Fracture
17%
Percutaneous Coronary Intervention
17%
Cancer-associated
17%
Medicine and Dentistry
Venous Thromboembolism
100%
Malignant Neoplasm
81%
Platelet
58%
Anticoagulation
56%
Thrombosis
55%
Thrombocytopenia
48%
Direct Oral Anticoagulant
45%
Atrial Fibrillation
37%
Bleeding
34%
Chemotherapy
31%
Hematologic Malignancy
28%
Cohort Analysis
27%
Procoagulant
26%
Thrombin
24%
Arterial Thromboembolism
22%
Thrombocyte Adhesion
21%
Deep Vein Thrombosis
21%
Antiplatelet
20%
Thrombocyte Activation
20%
Diseases
20%
Blood Stasis
20%
Cancer
19%
Apixaban
19%
Major Bleeding
19%
Hazard Ratio
18%
COVID-19
17%
Blood Clot Lysis
17%
Superior Vena Cava Syndrome
17%
Factor XI
17%
Insulin
17%
Glucose
17%
Low Molecular Weight Heparin
16%
Disease Course
15%
Thromboprophylaxis
15%
Maturity Onset Diabetes of the Young
15%
Cancer Treatment
14%
Cumulative Incidence
14%
Thromboembolism
14%
Non Small Cell Lung Cancer
12%
Retrospective Cohort Study
12%
Antiphospholipid Antibody
11%
Solid Malignant Neoplasm
11%
Acetylsalicylic Acid
11%
Phlebothrombosis
11%
Antithrombotic
11%
Thrombotic Thrombocytopenic Purpura
11%
Fibrinogen
10%
CHA2DS2-VASc Score
10%
Computer Assisted Tomography
10%
Rivaroxaban
10%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
72%
Venous Thromboembolism
68%
Acetylsalicylic Acid
64%
Atrial Fibrillation
60%
Direct Oral Anticoagulant
53%
Antiplatelet
52%
Thrombocytopenia
52%
Thrombosis
47%
Bleeding
42%
Cohort Study
37%
Thrombin
35%
Clopidogrel
34%
Low Molecular Weight Heparin
33%
Anticoagulant Agent
31%
Arterial Thromboembolism
29%
Hematologic Malignancy
27%
Antithrombocytic Agent
26%
Chemotherapy Regimens
19%
Diseases
18%
Brain Hemorrhage
18%
Apixaban
17%
Adenosine Diphosphate
17%
Purinergic P2Y12 Receptor
15%
Acute Heart Infarction
14%
Non Small Cell Lung Cancer
12%
Arachidonic Acid
12%
Polypharmacy
11%
Integrin
11%
Solid Malignant Neoplasm
10%
Antithrombotic Therapy
10%
Blood Clotting Factor 7
10%
Procoagulant
10%
Blood Clotting Factor
10%
Acute Coronary Syndrome
9%
Brain Metastasis
9%
Prasugrel
9%
Ticagrelor
9%
Brain Cancer
9%
Maturity Onset Diabetes of the Young
8%
Daboia palaestinae
8%
Thrombogenicity
8%
Lung Cancer
8%
Superior Cava Vein Syndrome
8%
Blood Stasis
8%
Recombinant Blood Clotting Factor 7a
8%
Beta Thalassemia
8%
Blood Clotting Factor 11
8%
Thalassemia Major
8%
Tranexamic Acid
8%
Mucosal Bleeding
8%
